GlassScriptPhysician profile
Ginger K Lovingood
NPI 1780900373
$4,611.18
in general payments reported to CMS, 2019-2025
28 companies · $1,197 in 2025
The $1,197 reported for 2025 was more than what 83% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $679 · 2020: $139 · 2021: $81.27 · 2022: $622 · 2023: $827 · 2024: $1,066 · 2025: $1,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,978 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,977.59 |
| Education | $111.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $758.94 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $475.56 | 2019-2025 | Ingrezza |
| Abbvie INC. | $345.68 | 2021-2024 | |
| Alkermes, INC. | $337.29 | 2022-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $298.27 | 2019-2025 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $271.48 | 2022-2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $264.05 | 2019-2025 | Trintellix |
| Lundbeck LLC | $249.58 | 2019-2025 | Rexulti |
| Acadia Pharmaceuticals INC | $187.46 | 2019-2025 | Nuplazid |
| Neos Therapeutics, LP | $123.19 | 2024-2025 | Adzenys Xr-Odt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $120.92 | 2022-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $120.44 | 2019-2025 | Fanapt, Hetlioz |
| Tris Pharma INC | $116.73 | 2023-2024 | Dyanavel Xr |
| Almatica Pharma LLC | $115.79 | 2022-2024 | Loreev Xr |
| Sunovion Pharmaceuticals INC. | $114.39 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $103.87 | 2022-2025 | Azstarys |
| Idorsia Pharmaceuticals US INC | $92.67 | 2023-2025 | Quviviq, Quviviq |
| Bausch Health US, LLC | $84.68 | 2022-2024 | Aplenzin |
| Ironshore Pharmaceuticals INC. | $74.37 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $66.42 | 2024-2025 | Spravato |
| Supernus Pharmaceuticals, INC. | $65.61 | 2022-2023 | Qelbree |
| Avanir Pharmaceuticals, INC. | $54.20 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $51.05 | 2025 | Cobenfy |
| Allergan, INC. | $42.85 | 2019 | |
| Arbor Pharmaceuticals, INC. | $27.98 | 2019 | |
| Merck Sharp & Dohme LLC | $17.34 | 2023 | Belsomra |
| Adlon Therapeutics L.P. | $17.26 | 2019 | |
| Shire North American Group INC | $13.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ginger Lovingood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.